Gujarat Themis Biosyn Limited (BOM:506879)

Market Cap	46.22B -7.4%
Revenue (ttm)	1.74B +17.5%
Net Income	486.87M +9.2%
EPS	4.47 +9.1%
Shares Out	130.15M
PE Ratio	79.43
Forward PE	n/a
Dividend	0.67 (0.19%)
Ex-Dividend Date	Sep 23, 2026

Volume	42,377
Open	346.10
Previous Close	351.30
Day's Range	338.00 - 367.55
52-Week Range	225.75 - 479.45
Beta	0.64
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About Gujarat Themis Biosyn

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals, medicinal chemicals, and active pharmaceutical ingredients in India and internationally. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O, an antibiotic for the treatment of traveller’s diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1981
• Employees: 221
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 506879

Financial Performance

In fiscal year 2026, Gujarat Themis Biosyn's revenue was 1.66 billion, an increase of 9.96% compared to the previous year's 1.51 billion. Earnings were 466.82 million, a decrease of -4.29%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 23, 2026

Data Sources Report a data error